Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Context Therapeutics (NASDAQ:CNTX) from a strong sell rating to a hold rating in a research note published on Tuesday,Zacks reports.

Other research analysts have also issued reports about the stock. Weiss Ratings raised shares of Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 15th. Citigroup restated an “outperform” rating on shares of Context Therapeutics in a report on Thursday, August 6th. Wall Street Zen lowered shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Finally, Lifesci Capital cut Context Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $6.40.

Context Therapeutics Stock Performance

NASDAQ:CNTX opened at $0.22 on Tuesday. Context Therapeutics has a 52 week low of $0.18 and a 52 week high of $3.62. The firm’s fifty day moving average is $0.29 and its 200-day moving average is $1.39. The firm has a market cap of $19.86 million, a P/E ratio of -0.47 and a beta of 1.77.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. As a group, sell-side analysts anticipate that Context Therapeutics will post -0.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CNTX. BlackRock Inc. purchased a new stake in shares of Context Therapeutics in the 2nd quarter worth about $3,417,000. Octagon Capital Advisors LP bought a new stake in Context Therapeutics during the first quarter worth about $13,755,000. Blue Owl Capital Holdings LP purchased a new stake in Context Therapeutics in the second quarter worth about $1,625,000. ADAR1 Capital Management LLC purchased a new stake in Context Therapeutics in the second quarter worth about $416,000. Finally, Russell Investments Group Ltd. increased its stake in shares of Context Therapeutics by 8,907.7% during the third quarter. Russell Investments Group Ltd. now owns 671,074 shares of the company’s stock valued at $202,000 after purchasing an additional 663,624 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

About Context Therapeutics

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens. Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.